Strong organic growth masked by Raipur losses, breakeven delayed
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit EBITDA margin guidance (21% target, 21.5% delivered Q2); FY27 growth guidance 15%-16% on track (15.8% H1). Missed Raipur breakeven timeline by 2 quarters.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered solid 14% revenue growth and 45% PAT growth with 21.5% EBITDA margin, supporting prior guidance. However, Raipur's ₹9 Cr Q2 loss and breakeven timeline slipped from Q3 FY27 to Q1 FY28, a material miss. Organic momentum strong (Howrah +25% H1, occupancy +290 bps), but ₹10-13 Cr annual drag from Raipur and upcoming Jamshedpur losses through FY28 will pressure overall returns and ROE/ROCE targets.
₹135.6 Cr
Revenue · +14.1% YoY₹15.4 Cr
Reported PAT · +45.2% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
EBITDA margin expanded 150 bps to 21.5% in Q2 FY27
METEBITDA ₹29.8 Cr / Revenue ₹135.6 Cr = 22% margin, prior year Q2 at ~20%, supporting 150+ bps expansion
PAT margin expanded 230 bps to 11.1% in Q2
METPAT ₹15.4 Cr / Revenue ₹135.6 Cr = 11.4%, prior year Q2 at ~8.8%, supporting ~260 bps expansion — slightly overstated
Network occupancy improved 260 bps to 50.3% YoY
MET50.3% vs 47.4% prior year Q2 = 290 bps improvement, not 260
Raipur on track to breakeven in Q1 FY28 after ~3-year ramp
MISSOriginally guided Q3 FY27; slipped to Q1 FY28. Q2 losses ₹9 Cr (vs ₹-6.5 Cr for H1), deteriorating trend
H1 FY27 PAT growth 53.9% to ₹28.1 Cr
METQ2 ₹15.4 Cr PAT; H1 PAT ₹28.1 Cr implies Q1 ₹12.7 Cr. Q1 growth to ₹12.7 Cr from prior year ₹8.1 Cr = 57% growth, H1 growth 53.9% aligns
Earnings quality
What changed since the last call
Raipur breakeven timeline
DowngradeGuided Q3 FY27; slipped to Q1 FY28 (2 quarters). Q2 losses ₹9 Cr; H1 ₹6.5 Cr. Competitive entry and talent attrition cited.
FY27 EBITDA margin guidance
MaintainedMaintained at 21%; Q2 delivered 21.5%. H1 at 21%, on track for ₹110-115 Cr full-year EBITDA target.
Jamshedpur construction timeline
NeutralMarch-April 2027 commissioning (late Q4 FY27 / early Q1 FY28). 155 beds, ~₹10 Cr EBITDA losses expected FY28.
International patient inflow recovery
DowngradeDescribed as 'slow recovery' from Bangladesh, process changes initiated. Visa request letters increasing but below prior estimates.
The Q&A
Analysts pressed hard on Raipur (breakeven timing, competition from Artemis, talent attrition), occupancy sustainability (Agartala at 54%, Howrah at 45%), and whether 80% occupancy is achievable. Management defended strategy but was cautiously realistic on timelines and execution. No dodging, some hedging on future occupancy targets.
Raipur occupancy & losses — Richa Chowdhary, Electrum PMS
AnsweredARPOB drop minor; seasonal factors in Q2, mix change in specialties. Raipur losses ₹9 Cr Q2, ₹6.5 Cr H1, in line with expectations. Breakeven Q1 next year on monthly basis.
Growth drivers & sustainability — Aditya Chheda, InCred Asset Management
PartialDriven by productivity increases and higher-end specialty mix focus. Cautiously optimistic on momentum, but regional challenges in Agartala (recruitment, state competition) being addressed.
FY27 guidance & capex — Aditya Chheda, InCred Asset Management
Answered15%-16% FY27 growth on track. Raipur lease ₹4 Cr/yr, Jamshedpur ~₹4 Cr/yr. Debt + equity mix for expansion.
Hospital expansion strategy — Avinish Balasubramaniam, Brookfields Estate
PartialManagement intent on growth, adding hospitals every couple years. Jamshedpur March-April 2027. Actively scouting Eastern/Central India and M&A. No committed timeline or bed addition target disclosed.
Agartala hospital occupancy — Anubhav Mukherjee, Prescient Capital
AnsweredAgartala in Northeast, operational challenges (consultant recruitment difficult but improving). Hopeful to reach 70% soon. Brownfield bed additions planned once occupancy optimizes.
Ranchi hospital & M&A — Anubhav Mukherjee, Prescient Capital
AnsweredRanchi MOU signed but not executed; owner had legal issues/land dispute. Deviated; now focused on Jamshedpur in Jharkhand. Opportunities constantly evaluated.
Raipur breakeven delay — Naysar Shah, AMPL Asset Management
AnsweredClinical talent attrition due to newer entrants in market; bridged gap, back on track. Delayed breakeven slightly but within control. On track now.
Exit occupancy Q4 guidance — Naysar Shah, AMPL Asset Management
AnsweredAverage occupancy expected 25%-30% mark by end of Q4.
Bed expansion capacity — Naysar Shah, AMPL Asset Management
AnsweredBoth hospitals can add 100 beds each. Activation will depend on occupancy optimization.
Raipur insurance empanelment — Naysar Shah, AMPL Asset Management
Answered~70% of insurance players empaneled. More to follow. Government patient strategy (Ayushman Bharat) being pursued alongside.
Cash collections & ARPOB — Naysar Shah, AMPL Asset Management
AnsweredCorporate ARPOB works CGHS rates (slightly better than Ayushman). Payment cycle 90 days.
Government patient strategy at mature hospitals — Naysar Shah, AMPL Asset Management
PartialMindful of specialty mix and receivable cycle when adding these patients. Doing it optimally at Agartala and Raipur where required. Howrah also taking but volume limited.
Supreme Court trade margin ruling — Dixit Doshi, Whitestone Financial Advisors
PartialClarity to come Nov 2 week. Health care to be seen on overall basis. Service pricing basis to be corrected to maintain margins.
Growth drivers & occupancy trajectory — Darsh Mahida, JK Capital
Answered11% inpatient volume increase network-wide, occupancy improved to 50.3%. Howrah +25% H1, Dum Dum double-digit. Primary driver occupancy ramp and incremental ARPOB.
Mature hospital occupancy targets — Darsh Mahida, JK Capital
AnsweredHowrah: focusing high-end specialties (orthopedics 120+ procedures/month); Salt Lake at 68% occupancy. Dum Dum at ~74%, limited room. Agartala 55%, working on cardiology/nephrology. Target 70% near future.
Oncology revenue contribution — Darsh Mahida, JK Capital
AnsweredOncology ~4% revenue contribution, growing quarterly. International patient flow showing slow recovery, not back to prior estimates. Processes changed for Bangladesh patient movement.
Balance sheet & leverage — Jeeva, individual investor
AnsweredCash ~₹45 Cr in mutual funds. Borrowings ~₹35 Cr. Debt-equity very low. Will take good mix of debt/equity for Jamshedpur and newer hospitals.
Occupancy ceiling at 80% — Naysar Shah, AMPL Asset Management
AnsweredVery difficult. Requires long-stay patients, insurance approvals, bed-change downtime. Achieved in past (Dum Dum restructure) but beyond 80% is very challenging. Realistic peak ~70%.
ALOS optimization — Naysar Shah, AMPL Asset Management
AnsweredAlready optimized ALOS at Dum Dum and Salt Lake. Salt Lake ALOS 2.9-3.0, Dum Dum down from 5.5 to 4.3. Best-practice levels considering treatment standards.
Doctor retention in new markets — Aditya Chheda, InCred Asset Management
AnsweredEngagement efforts at consultants level; controlled and synchronized. Raipur faced competitive offerings; bridged gap. Jamshedpur market better on product/consultant retention. Conferences organized at Agartala, Raipur to engage consultants.
Raipur FY28 losses & Jamshedpur — Aditya Chheda, InCred Asset Management
AnsweredRaipur FY28: net positive by minor amount (minor loss at most). Jamshedpur: ~₹10 Cr loss at EBITDA level FY28.
Raipur FY27 losses — Aditya Chheda, InCred Asset Management
AnsweredRaipur FY27 losses ~₹10 Cr.
Artemis competition at Raipur — Anubhav Mukherjee, Prescient Capital
AnsweredArtemis entered Raipur post-GPT launch. Led to talent attrition; recovered. Competitively advantaged on Eastern India play; still room for multiple players. Made good that attrition, on track now.
East & Central India expansion — Anubhav Mukherjee, Prescient Capital
AnsweredDefinite potential in Eastern India offers increased focus. Been in region for time; understand well. Competitive advantage in expansion opportunities. Space for multiple players.
Guidance
FY27 revenue growth 15%-16% YoY
HighH1 at 15.8% (₹261.8 Cr); organic momentum strong; H2 typically slower but target achievable
FY27 EBITDA margin target 21%
HighQ2 delivered 21.5%; H1 at 21%. Prior guidance raised from 20.2% to 21%; corroborated
EBITDA expectations ₹110-115 Cr full year
MediumH1 at ₹56 Cr; full-year trajectory ~₹110-120 Cr on track. Dependent on Raipur ramp-up pace
Annual capex ~₹100 Cr for expansion (mentioned in Q&A, not explicit)
LowAnalyst reference to capex guidance not directly confirmed; debt + equity mix planned for Jamshedpur/newer hospitals
Risks the call surfaced
Raipur execution & competition
HighRaipur occupancy at low levels (~30%). Artemis entry post-launch led to talent attrition. Breakeven slipped Q3→Q1 FY28. ₹9 Cr Q2 loss.
Occupancy sustainability & cap
MediumSalt Lake at 68% occupancy (bed-constrained). Dum Dum at 74% (limited room). Agartala at 55% (recruitment challenges). Management admits 80%+ occupancy 'very difficult' and 'very few hospitals can do it.'
International patient recovery
MediumBangladesh international patient inflow showing 'slow recovery,' not back to prior run-rate per management. Changes in visa processes impacting patient movement. International patients at 53.7% occupancy level.
Supreme Court trade margin ruling
MediumSupreme Court issued judgment on trade margins for essential medicines. Impact to be clarified Nov 2 week. Health care consumable mix may face pressure if ruling applies to hospital procurement.
Jamshedpur greenfield execution
MediumJamshedpur 155-bed hospital commissioning March-April 2027 (Q4 FY27). Expected ₹10 Cr EBITDA loss in FY28. Consultant retention strategy evolving (conferences organized, engagement at higher level). New market operational learning curve.
Management
Score 7/10. Clear on operational metrics and segment performance. Transparent on Raipur challenges and breakeven delay. Hedged on specific occupancy targets and acquisition timeline. Some evasiveness on government patient strategy rationale. Hit EBITDA margin guidance (21% target, 21.5% delivered Q2). FY27 growth 15%-16% on track (15.8% H1). Missed Raipur breakeven (Q3 FY27→Q1 FY28, 2-quarter slip). Organic growth strong (Howrah +25% H1, Dum Dum +12% H1).
1 · Q3 Q4 FY27
Raipur occupancy ramp, clinical talent stabilization post-attrition
2 · Mar-Apr 2027
Jamshedpur 155-bed hospital commissioning; incremental losses initially
3 · Q1 FY28
Raipur expected breakeven on monthly basis
Organic momentum strong (Howrah +25% H1, occupancy +290 bps), but ₹10-13 Cr annual drag from Raipur and upcoming Jamshedpur losses through FY28 will pressure overall returns and ROE/ROCE targets.
Informational and educational content only. Not investment advice.